Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5% ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Medical equipment supplier and pharma services outlet Thermo Fisher Scientific also said on Wednesday it estimated a $400 ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...